Title of Invention	A PROCESS FOR THE PRODUCTION OF THE ANTRHRANILIC ACID AMIDE COMPOUNDS
Abstract	A process for the production of the anthranilic acid amide compounds of formula I in which A W stands for the group =NR2, stands for oxygen, sulfur, two hydrogen atoms or the group =NR8, stands for the group =NR10 or =N-, -N(R10) - (CH2) - , branched or unbranched C,.6 allcyl or the group or A, Z and R1 together form the group m, n and o stand for 0-3, q stands for 1-6, Ra, Rb, Rc, Rd, R , Rf, independently of one another, stand for hydrogen, C1-4 alkyl or the group =NR10, and/or Ra and/or Rb can form a bond with Rc and/or Rd or Rc can form a bond with Re and/or Rf, or up to two of radicals Ra-Rf can close a bridge with up to 3 C-atoms each to form R1 or R2,

Title of Invention

A PROCESS FOR THE PRODUCTION OF THE ANTRHRANILIC ACID AMIDE COMPOUNDS

Abstract

A process for the production of the anthranilic acid amide compounds of formula I in which A W stands for the group =NR2, stands for oxygen, sulfur, two hydrogen atoms or the group =NR8, stands for the group =NR10 or =N-, -N(R10) - (CH2) - , branched or unbranched C,.6 allcyl or the group or A, Z and R1 together form the group m, n and o stand for 0-3, q stands for 1-6, Ra, Rb, Rc, Rd, R , Rf, independently of one another, stand for hydrogen, C1-4 alkyl or the group =NR10, and/or Ra and/or Rb can form a bond with Rc and/or Rd or Rc can form a bond with Re and/or Rf, or up to two of radicals Ra-Rf can close a bridge with up to 3 C-atoms each to form R1 or R2,

Full Text	FORM 2 THE PATENTS ACT 1970 [39 OF 1970] & THE PATENTS RULES, 2003 COMPLETE SPECIFICATION [See Section 10; rule 13] "A PROCESS FOR THE PRODUCTION OF THE ANTRHRANILIC ACID AMIDE COMPOUNDS" SCHERING AKTIENGESELLSCHAFT, of Mullerstrasse 178, D- 13342 Berlin, Germany and NOVARTIS AKTIENGESELLSCHAFT, of Schwarzwaldallee 215, CH-4058 Basel, Switzerland, GRANTED The following specification particularly describes the invention and the manner in which it is to be performed: The invention relates to anthranilic acid amides and their use as pharmaceutical agents for treatment of diseases that are triggered by persistent angiogenesis as well as their intermediate products for the production of anthranilic acid amides. Persistent angiogenesis can be the cause of various diseases such as psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy, fibrotic diseases, such as cirrhosis of the liver, mesangial-cell-proliferative diseases, and arteriosclerosis or can result in a progression of these diseases. A direct or indirect inhibition of the VEGF receptor can be used for the treatment of such diseases and other VEGF-induced pathological angiogenesis and vascular permeable conditions, such as tumor vascularization. For example, it is known that by soluble receptors and antibodies against VEGF, the growth of tumors can be inhibited. Persistent angiogenesis is induced by the VEGF factor via its receptor. So that VEFG can exert this action, it is necessary that VEGF bonds to the receptor and a tyrosine phosphorylation is brought about. Phenyl-anthranilamide derivatives are already known that are used as angiotensin II-antagonists (EP 564 356) and as antiinflammatory agents and anti-ulcera compounds (U.S. 3,409,668). It has now been found that compounds of general formula I in which A W stands for the group =NR2, stands for oxygen, sulfur, two hydrogen atoms or the group =NR8, stands for the group =NR10 or =N-, -N(R10) - (CH2) -, branched or unbranched C1-6 alkyl or the group or A, Z and R1 together form the group m, n and o stand for 0-3, q stands for 1-6, R , Rb, Rc, Rd, R , Rf, independently of one another, stand for hydrogen, C1.4 alkyl or the group =NR10, and/or R and/or Rb can form a bond with Rc and/or Rd or Rc can form a bond with Re and/or Rf, or up to two of radicals Ra-Rf can close a bridge with up to 3 C-atoms each to form R1 or R2, X stands for the group =NR9 or =N-, Y stands for the group -(CH2)p/ p stands for 1-4, R1 stands for C1_6 alkyl that is unsubstituted or is optionally substituted in one or more places with halogen, C1-6 alkyl, in one or more places with halogen, or aryl or heteroaryl that is substituted with C1-6 alkoxy, with the exception of compounds in which aryl is bonded right in the =NR2 group in the meaning of A, R2 stands for hydrogen or C1-6 alkyl or forms a bridge with up to 3 ring members with Ra-Rf from Z or to form Rv R3 stands for monocyclic or bicyclic aryl or heteroaryl that is unsubstituted or optionally substituted in one or more places with halogen, C1-6 alkyl, C1-6 alkoxy or hydroxy, R4, R5, R6, and R7, independently of one another, stand for hydrogen, halogen, or C1-6 alkoxy, C1-6 alkyl or C1-6 carboxylalkyl that is unsubstituted or optionally substituted in one or more places with halogen, or R5 and R6 together form the group 0 CH2 0 R8, R9, and R10, independently of one another, stand for hydrogen or C1-6 alkyl, as well as their isomers and salts, stop a tyrosine phosphorylation or persistent angiogenesis and thus prevent the growth and propagation of tumors. If R2 forms a bridge to R1, heterocycles are produced to which R1 is fused. For example, there can be mentioned: If Ra, Rfa, Rc, Rd, Re, Rf/ independently of one another, represent hydrogen or C1-4 alkyl, Z forms an alkyl chain. If Ra and/or Rb form a bond with Rc and/or Rd or Rc and/or Rd form a bond with Re and/or Rf, Z stands for an alkenyl or alkinyl chain. If Ra-Rf form a bridge on their own, Z represents a cycloalkyl or cycloalkenyl group. If up to two of radicals Rg-Rf form a bridge with up to 3 C atoms to R1, Z together with R1 is a benzo- or hetaryl-condensed (Ar) cycloalkyl. For example, there can be mentioned: If one of radicals Rg-Rf closes a bridge to form R2, a nitrogen heterocycle that can be separated from R1 by a group is formed. For example, there can be mentioned: Alkyl is defined in each case as a straight-chain or branched alkyl radical, such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, pentyl, isopentyl or hexyl, whereby C1-4 alkyl radicals are preferred. Cycloalkyl is defined respectively as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. Cycloalkenyl is defined respectively as cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, whereby the linkage can take place both to the double bond and to the single bonds. Halogen is defined respectively as fluorine, chlorine, bromine or iodine. The alkenyl and alkinyl substituents are in each case straight-chain or branched and contain 2-6 C atoms, preferably 2-4 C atoms. For example, the following radicals can be mentioned: vinyl, propen-1-yl, propen-2-yl, but-1-en-l-yl, but-l-en-2-yl, but-2-en-i-yl, but-2-en-2-yl, 2-methyl-prop-2-en-l-yl,- 2-methyl-prop-1-en-l-yl, but-l-en-3-yl, ethinyl, prop-1-in-l-yl, but-l-in-1-yl, but-2-in-l-yl, but-3-en-l-yl, allyl. In each case, the aryl radical has 6-12 carbon atoms, such as, for example, naphthyl, biphenyl and especially phenyl. In each case, the heteroaryl radical can be benzocondensed. For example, there can be mentioned as 5-ring heteroaromatic compounds: thiophene, furan, oxazole, thiazole, imidazole, pyrazole and benzo derivatives thereof, and as 6-ring-heteroaromatic compounds pyridine, pyrimidine, triazine, quinoline, isoquinoline and benzo derivatives, whereby in the case of benzocondensed heteroaryl radicals, the binding can be both to the heterocycle and to the benzo ring. In each case, the aryl radical and the heteroaryl radical can be substituted by the same or a different component in 1, 2 or 3 places with halogen, C1-4 alkoxy, nitro, trifluoromethyl, trifluoromethoxy, cyano, SOqR5 or C1-4 alkyl, whereby q stands for 0-2. If an acid group is included, the physiologically compatible salts of organic and inorganic bases are suitable as salts, such as, for example, the readily soluble alkali and alkaline-earth salts as well as N-methyl-glucamine, dimethyl glucamine, ethyl glucamine, lysine, 1,6-hexadiamine, ethanolamine, glucosamine, sarcosine, serinol, tris-hydroxy-methyl-amino-methane, aminopropanediol, Sovak base, l-amino-2,3,4-butanetriol. If a basic group is included, the physiologically compatible salts of organic and inorganic acids are suitable, such as hydrochloric acid, sulfuric acid, phosphoric acid, citric acid, tartaric acid, i.a. Those compounds of general formula I in which A stands for the group =NR2, W stands for oxygen, sulfur, two hydrogen atoms or the group =NR8, Z stands for the group =NR10, =N- or or A, Z and R1 together form the group -N(R10) - (CH2)4- branched or unbranched C1-6 alkyl or the group m, n, and o stand for 0-3, q stands for 1-6, R , R. , R , R.; R and R,, independently of one another, stand for hydrogen, C1-4 alkyl or the group =NR10, X stands for the group =NR9 or =N-, Y stands for the group -(CHJ , p stands for 1-4, R1 stands for phenyl, pyridyl, 5-chloro- 2,3-dihydroindenyl, 2,3-dihydroindenyl, thienyl, 6-fluoro-lH-indol-3-yl, naphthyl, 1,2,3,4 -1etrahydronaphthyl, benzo-1,2,5-oxadiazole, 6,7-dimethoxy-1,2,3,4-tetrahydro-2-naphthyl or for phenyl or pyridyl that is substituted in one or more places with C1-C4 alkyl, C1- C4 alkoxy, hydroxy, halogen, or trifluoromethyl, or for the group whereby phenyl, substituted phenyl or naphthyl is not right in the =NR2 group in the meaning of A, R2 stands for hydrogen or C1-6 alkyl or forms a bridge with up to 3 ring members with Ra-Rf from Z or to form R1, R3 stands for monocyclic or bicyclic aryl or monocyclic or bicyclic heteroaryl that is unsubstituted or optionally substituted in one or more places with halogen, C1-6alkyl, C1-6 alkoxy or hydroxy, R4, R5, R6 and R7, independently of one another, stand for hydrogen, halogen or C1-6 alkoxy or C1-6 alkyl that is unsubstituted or optionally substituted in one or more places with halogen, or R5 and R6 together form the group R8, R9 and R10, independently of one another, stand for hydrogen or C^ alkyl, as well as their isomers and salts, have proven especially effective. preferred are compounds of general formula I stands for the group =NR2, stands for oxygen, sulfur or two hydrogen atoms, stands for the group =NR10, =N-, -N(R10) (CH2) - or the group or A, Z and R1 together form the group m, n and o stand for 0-3, q stands for 1-6, Ra' Rb' Rc' Rd' Re' Rf independently of one another, stand for hydrogen or methyl or the group =NR10, X stands for the group =NR9 or =N-, Y stands for the group -CH2-, R1 stands for phenyl, pyridyl, 5-chloro- 2,3-dihydroindenyl, 2,3-dihydroindenyl, thienyl, 6-fluoro-lH-indol-3-yl, naphthyl, 1,2,3,4-tetrahydronaphthy1, benzo-l,2,5-oxadiazole, 6,7-dimethoxy-l,2,3,4-tetrahydro-2-naphthyl, or for phenyl or pyridyl that is substituted in one or more places with C1-C4 alkyl, C1-C4 alkoxy, hydroxy, halogen, trifluoromethyl, or for the group whereby phenyl, or substituted phenyl or naphthyl is not right in the =NR2 group in the meaning of A, stands for hydrogen or methyl, stands for pyridyl or phenyl, pyridyl or 1,2,3,4-tetrahydronaphthyl that is substituted with hydroxy, halogen, methyl or methoxy, or the group R5 and R6, independently of one another, stand for hydrogen, halogen, methyl, methoxy or trifluoromethyl, R4 and R7, independently of one another, stand for hydrogen or halogen, R9 stands for hydrogen, R10 stands for hydrogen or methyl, as well as their isomers and salts. Those compounds of general formula I in which A stands for the group =NR2, _ W stands for oxygen, z stands for the group =NR10, =N-, -N(R10)- or A, Z and R1 together form the group (CH2) - or the group m, n and o stand for 0-3, q stands for 1-6, Ra, Rb, Rc, Rd, Re, Rf, independently of one another, stand for hydrogen or methyl or the group =NR1°, X stands for the group =NR9 or =N-, Y stands for the group -CH2-, R1 stands for phenyl, pyridyl, 5-chloro- 2,3-dihydroindenyl, 2,3-dihydroindenyl, thienyl, 6-fluoro-1H-indol-3-yl, naphthyl, 1,2,3,4-tetrahydronaphthyl, benzo-1,2,5-oxadiazole or 6,7-dimethoxy-1,2,3,4-tetrahydro-2-naphthyl or for a phenyl or pyridyl that is substituted in one more places with C1-C4 alkyl, C1-C4 alkoxy, hydroxy, halogen, trifluoromethyl, or for the group whereby phenyl, or substituted phenyl or naphthyl is not right in the =NR2 group in the meaning of A, stands for hydrogen or methyl, stands for pyridyl or for phenyl, pyridyl or 1,2,3,4 -tetrahydronaphthyl that is substituted in one or more places with hydroxy, halogen, methyl or methoxy, or for the group R5 and R6, independently of one another, stand for hydrogen, halogen, methyl, methoxy, or trifluoromethyl, R4 and R7, independently of one another, stand for hydrogen and halogen, R9 stands for hydrogen, R10 stands for hydrogen or methyl, as well as their isomers and salts, have proven quite especially effective. Those compounds of general formula I in which stands for the group =NR2, stands for sulfur, stands for the group =NR10, =N-, -N(R10) (CH2)4 - or the group or A, Z and R1 together form the group n and o stand for 0-3, stands for 1-6, Ra' Rb' Rc' Rd' Re' Rf/ independently of one another, stand for hydrogen or methyl or the group =NR10, X stands for the group =NR9 or ==N-, Y stands for the group -CH2-, R stands for phenyl, pyridyl, 5-chloro- 2,3-dihydroindenyl, 2,3-dihydroindenyl, thienyl, 6-fluoro-lH-indol-3-yl, naphthyl, 1,2,3,4-tetrahydronaphthyl, benzo-1,2,5-oxadiazole or 6,7-dimethoxy-1,2,3,4-tetrahydro-2-naphthyl or for phenyl or pyridyl that is substituted in one or more places with C1-C4 alkyl, C1-4 alkoxy, hydroxy, halogen, trifluoromethyl, or for the group whereby phenyl, or substituted phenyl or naphthyl is not right in the =NR2 group in the meaning of A, R2 stands for hydrogen or methyl, R3 stands for pyridyl or for phenyl, pyridyl or l,2,3,4-tetrahydronaphthyl that is substituted in one or more places with hydroxy, halogen, methyl or methoxy, or for the group R5 and R6, independently of one another, stand for hydrogen, halogen, methyl, methoxy or trifluoromethyl, R4 and R7, independently of one another, stand for hydrogen and halogen, R9 stands for hydrogen, R10 stands for hydrogen or methyl, as well as their isomers and salts, have also proven quite especially effective. Those compounds of general formula I in which A stands for the group =NR2, W stands for two hydrogen atoms, Z stands for the group =NR10, =N-, -N(R10)- or A, Z, and R1 together form the group (CH2) - or the group m, n and o stand for 0-3, q stands for 1-6, Ra, Rb, Rc, Rd, Re, Rf, independently of one another, stand for hydrogen or methyl or the group =NR10, X stands for the group =NR9 or =N- , Y stands for the group -CH2-, R1 stands for phenyl, pyridyl, 5-chloro- 2,3-dihydroindenyl, 2,3-dihydroindenyl, thienyl, 6-fluoro-lH-indol-3-yl, naphthyl, 1,2,3,4-tetrahydronaphthyl, benzo-1,2,5-oxadiazole or 6,7-dimethoxy-1,2,3,4-tetrahydro-2-naphthyl or for a phenyl or pyridyl that is substituted in one or more places with C1-4 alkyl, C1-4 alkoxy, hydroxy, halogen, or trifluoromethyl, or for the group whereby phenyl, or substituted phenyl or naphthyl is not right in the =NR2 group in the meaning of A, stands for hydrogen or methyl, stands for pyridyl or for phenyl, pyridyl or 1,2,3,4 -tetrahydronaphthyl that is substituted in one or more places with hydroxy, halogen, methyl or methoxy, or for the group RA and R7, independently of one another, stand for hydrogen, halogen, methyl, methoxy or trifluoromethyl, R5 and R6, R,10 independently of one another, stand for hydrogen and halogen, stands for hydrogen, stands for hydrogen or methyl, as well as their isomers and salts, have also proven quite especially effective. The compounds according to the invention prevent a phosphorylation, i.e., certain tyrosine kinases can be inhibited selectively, whereby the persistent angiogenesis can be stopped. Thus, for example, the growth and the propagation of tumors is suppressed. The compounds of general formula I according to the invention also include the possible tautomeric forms and comprise the E- or Z-isomers, or, if a chiral center is present, also the racemates and enantiomers. The compounds of formula I and their physiologically compatible salts can be used based on their inhibitory activity relative to the phosphorylation of the VEGF receptor as a pharmaceutical agent. Based on their profile of action, the compounds according to the invention are suitable for the treatment of diseases that are caused by persistent angiogenesis. Since the compounds of formula I are identified as inhibitors of the tyrosine kinases KDR and FLT, they are suitable in particular for treatment of those diseases that are caused by the persistent angiogenesis that is triggered by the VEGF receptor or an increase of vascular permeability. The subject of this invention is also the use of compounds according to the invention as inhibitors of the tyrosine kinases KDR and FLT. The subjects of this invention are thus also pharmaceutical agents for the treatment of tumors. The compounds according to the invention can be used either alone or in a formulation as pharmaceutical agents for the treatment of psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy, fibrotic diseases, such as cirrhosis of the liver, mesangial-cell-proliferative diseases, arteriosclerosis and injuries to the nerve tissue. The compounds according to the invention can also be used in inhibiting the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents. In the treatment of injuries to the nerve tissue, a quick scar formation at the injury sites can be prevented with the compounds according to the invention, i.e., scars are prevented from forming before the axons are reconnected to one another. Reconstruction of the nerve connections thus would be facilitated. The ascites formation in patients also can be suppressed with the compounds according to the invention. The VEGF-induced edemas can also be suppressed. Such pharmaceutical agents, their formulations and uses are also the subject of this invention. The invention also relates to the use of the compounds of general formula I, for the production of a pharmaceutical agent for treatment of tumors, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy, fibrotic diseases, such as cirrhosis of the liver, mesangial-cell-proliferative diseases, arteriosclerosis, injuries to the nerve tissue, inhibition of the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents. To use the compounds of formula I as pharmaceutical agents, the latter are brought into the form of a pharmaceutical preparation, which in addition to the active ingredient for enteral or parenteral administration contains suitable pharmaceutical, organic or inorganic inert support media, such as, for example, water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc. The pharmaceutical preparations can be present in solid form, for example as tablets, coated tablets, suppositories, capsules or in liquid form, for example as solutions, suspensions or emulsions. Moreover, they optionally contain adjuvants such as preservatives, stabilizers, wetting agents or emulsifiers, salts for changing osmotic pressure or buffers. For parenteral use, in particular injection solutions or suspensions, especially aqueous solutions of the active compounds in polyhydroxyethoxylated castor oil, are suitable. As vehicle systems, surface-active adjuvants, such as salts of bile acids or animal or plant phospholipids, but also mixtures thereof as well as liposomes or components thereof can also be used. For oral use, especially tablets, coated tablets or capsules with talc and/or hydrocarbon vehicles or binders, such as, for example, lactose, corn or potato starch, are suitable. The application can also be carried out in liquid form, such as, for example, as juice, to which optionally a sweetener is added. The dosage of the active ingredients can vary depending on the method of administration, age and weight of the patient, type and severity of the disease that is to be treated, and similar factors. The daily dose is 0.5-1000 mg, preferably 50-200 mg, whereby the dose can be given as a single dose to be administered once or subdivided into 2 or more daily doses. The above-described formulations and forms for dispensing are also the subject of this invention. The production of the compounds according to the invention is carried out according to methods that are known in the art. For example, compounds of formula I are obtained in that a) A compound of formula II in which R4 to R7 have the above meaning and T is H or a protective group and A is halogen or OR13, whereby R13 means a hydrogen atom, C1-4 alkyl or C1-4 acyl, or a ring connects with T, first alkylates N and then converts COA into an amide and then optionally protective groups are cleaved or first converted into the amide and then N-alkylated, or b) A compound of formula III in which R4 to R7 have the above meaning and T means H or a protective group, is in orthometallated form, and then is converted into an amide by being caught with an electrophile, then the protective group is cleaved, and the amino group is alkylated, or c) A compound of formula IV in which R4 to R7 have the above meaning, and T means H or a protective group and B means halogen or O-filtrate, O-tosylate or O-mesylate, is converted into an amide, then the protective group is cleaved off, and the amino group is alkylated. The sequence of the steps can be reversed in all three cases. The amide formation is carried out according to methods that are known in the literature. For amide formation, a start can be made from a corresponding ester. The ester is reacted according to J. Org. Chem. 1995, 8414 with aluminum trimethyl and the corresponding amine in solvents, such as toluene, at temperatures of 0°C up to the boiling point of the solvent. This method can also be used in unprotected anthranilic acid esters. If the molecule contains two ester groups, both are converted into the same amide. When nitriles are used instead of ester, amidines are obtained under analogous conditions. For amide formation, however, all processes that are known from peptide chemistry are also available. For example, the corresponding acid can be reacted in aprotic polar solvents, such as, for example, dimethylformamide on an activated acid derivative, that can be obtained, for example, with hydroxybenzotriazole and a carbodiimide such as, for example, diisopropylcarbodiimide or else with preformed reagents, such as, for example, HATU (Chem. Comm. 1994, 201) or BTU, at temperatures of between 0°C and the boiling point of the solvent, preferably at 8 0°C with the amine at HATU preferably at room temperature. These methods can also be used in the unprotected anthranilic acids. For amide formation, the process can also be used on the mixed acid anhydride, imidazolide or azide. A prior protection of the amino group, for example as amide, is not necessary in all cases, but can affect the reaction advantageously. Isatoic acid anhydrides, in which the protection of the amino group and the activation of the acidic function are present at the same time, are a special starting material. If the amine is already converted into the BOC-protected compound, the ortho-position can be metallated by reaction with organometallic compounds, such as, for example, n-butyllithium, and then caught with isocyanates or isothiocyanates to form the anthranilamides or anthranilthioamides. A bromine or iodine substituent in this ortho-position facilitates the ortho-metallation by halogen-metal exchange. As solvents, ethers such as diethyl ether or tetrahydrofuran or hydrocarbon such as hexane, but also mixtures thereof, are suitable. The addition of variant in aqueous solution at weakly alkaline pH or by reaction with an anhydride in glacial acetic acid. The introduction of the halogens chlorine, bromine, iodine or the azido group via an amino group can also be carried out, for example, according to Sandmeyer, by the diazonium salts that are formed as intermediate products with nitrites being reacted with copper(I) chloride or copper(I) bromide in the presence of the corresponding acid such as hydrochloric acid or hydrobromic acid or with potassium iodide. If an organic nitrite is used, the halogens can be introduced into a solvent, such as, for example, dimethylformamide, e.g., by addition of methylene iodide or tetrabromomethane. The removal of the amino group can be achieved either by reaction with an organic nitrite in tetrahydrofuran or by diazotization and reductive boiling down of the diazonium salt with, for example, phosphorous acid optionally with the addition of copper(I) oxide. The introduction of fluorine can be carried out by, for example, Balz-Schiemann reaction of the diazonium tetrafluoroborate or according to J. Fluor. Chem. 76, 1996, 59-62 by diazotization in the presence of HFxpyridine and subsequent boiling-down optionally in the presence of a fluoride ion source, such as, e.g., tetrabutylammonium fluoride. The introduction of the azido group can be carried out after diazotization by reaction with sodium azide at room temperature. Ether cleavages are performed according to processes that are common in the literature. In this case, a selective cleavage products ior the production oi the compounds oi general ior-mula I according to the invention. Especially valuable are those intermediate products of general formula V in which A and W stand for oxygen, Z and R' together form a =C=0 group that is bonded to X, X stands for the group s=NR9 or =N-, Y stands for the group 'CH2~, R3 stands for pyridyl or phenyl or 1,2,3,4- tetrahydronaphthyl that is substituted by hydroxy, bromine, methyl or methoxy, R5 and R6 stand for hydrogen, cfclorine, methyl, methoxy or trifluoroethyl, R4 and R7 stand for hydrogen, R9 stands for hydrogen, as well as their isomers and salts. The intermediate products are partially active on their own and can thus also be used for the production of a pharmaceutical agent for the treatment of tumors, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy, fibrotic diseases, such as cirrhosis of the liver, mesangial-cell-proliferative diseases, arteriosclerosis, injuries to the nerve tissue, inhibition of the According to commonly used methods, such as, for example, crystallization, chromatography or salt formation, the isomer mixtures can be separated into enantiomers or E/Z-isomers. The production of the salts is carried out in the usual way, by a solution of the compound of formula I being mixed with the equivalent amount or an excess of a base or acid, which optionally is in solution, and the precipitate being separated or the solution being worked up in the usual way. If the production of the starting compounds is not described, the latter are known or can be produced analogously to known compounds or processes that are described here. Also subjects of this invention are the isatoic acid derivatives of general formula V V, in which R3-R7, X, Y and W have the meanings that are described in general formula I and in which A stands for the group =NR2 or oxygen, and Z and R1 together form a =C=0 group that is bonded to X, as well as their isomers and salts, as valuable intermediate reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents. can be achieved also in several groups that are present in the molecule. In this case, the ether is treated with, for example, boron tribromide in solvents such as dichloromethane at temperatures of between -100°C up to the boiling point of the solvent, preferably at -78°C. It is also possible, however, to cleave the ether by sodium thiomethylate in solvents such as dimethylformamide. The temperature can lie between room temperature and the boiling point of the solvent, preferably at 150°C. The N- or O-alkylation of amides such as the pyrid-2-one or 2-hydroxypyridine can be carried out according to methods that are known in the literature. An N-alkylation thus can be achieved with bases such as sodium hydride or potassium carbonate in solvents such as dimethylformamide and alkylation with alkyl halides such as methyl iodide. An O-alkylation with bases such as silver carbonate in solvents such as tetrahydrofuran or toluene or preferably mixtures thereof with alkyl halides, such as methyl iodide. An O-alkylation is also obtained during conversion with trialkyloxonium tetrafluoroborate in inert solvents such as methylene chloride. Mixtures of N- and O-alkyl derivatives are obtained in the reaction with diazomethane or trimethylsilyldiazomethane in solvents such as methanol or toluene, preferably in mixtures thereof at temperatures up to the boiling point of the solvent, but preferably at room temperature. The methods make possible a selective alkylation of the pyridone relative to the benzoic acid amide. The examples below explain the production of the compounds according to the invention without limiting the scope of the claimed compounds to these examples. Example 1.0 Production of N-(4-Pyridylmethyl)-anthranilic acid methyl ester Under nitrogen atmosphere, a mixture of 7.5 g of anthranilic acid methyl ester and 8.6 g of pyridine-4-carbaldehyde in 300 ml of methanol is mixed with 3 ml of acetic acid and stirred for 12 hours at room temperature. Then, the reaction mixture is mixed with 5.7 g of sodium cyanoborohydride (85%) and stirred for another 3 hours at room temperature. After this time, 1.14 g of sodium cyanoborohydride (85%) is added again and stirred for another 12 hours at room temperature. The reaction mixture is concentrated by evaporation. The residue is taken up in ethyl acetate and washed with saturated sodium bicarbonate solution and saturated sodium chloride solution. The dried organic phase is concentrated by evaporation, and the residue is purified with use of column chromatography on silica gel with use of hexane/ethyl acetate (1+1) . 10.2 g of the title compound with a melting point of 85.6°C is obtained. Example 2.0 Production of N-(3-phenylprop-l-yl)-N2-(4-pyridylmethyl)-anthranilic acid amide 242 mg of N-(4-pyridylmethyl)-anthranilic acid methyl ester is introduced into 3.5 ml of toluene, mixed with 2 02 mg of 3-phenylpropylamine and quickly mixed at 0°C with 0.75 ml of a 2 molar solution of trimethylaluminum in toluene. The reaction mixture is then heated for 1 hour at room temperature and then refluxed for 1 hour. After cooling, the reaction mixture is added to saturated sodium bicarbonate solution and extracted with ethyl acetate. The organic phase is washed, dried, filtered and concentrated by evaporation in a vacuum. The residue is then recrystallized from ethyl acetate. 265 mg of the title compound with a melting point of 117.4°C is obtained. Produced similarly to Example 2.0 are also the following compounds: [Key:] Beispiel = Example; Schmelzpunkt = Melting Point [Key:] Beispiel = Example; Schraelzpunkt = Melting Point [Key:] Beispiel = Example; Schmelzpunkt = Melting Point [Key:] Beispiel = Example; Schmelzpunkt = Melting Point [Key:] Beispiel = Example; Schmelzpunkt = Melting Point [Key:] Beispiel = Example; Schmelzpunkt = Melting Point 15 [Key:] Beispiel = Example; Schmelzpunkt = Melting Point [Key:] Beispiel = Example; Schmelzpunkt = Melting Point [Key:] Beispiel = Example; Schmelzpunkt = Melting Point Example 3.0 Production of N-(4-chlorobenzyl)-N2-(4-methoxybenzyl)anthranilamide 425 mg of N-(4-methoxybenzyl)isatoic acid anhydride is dissolved in 20 ml of tetrahydrofuran p.A., mixed with 234 mg of 4-chlorobenzylamine and refluxed for 4 hours. The reaction solution is concentrated by evaporation in a vacuum, taken up in ethyl acetate, washed, dried, filtered and concentrated by evaporation in a vacuum. The residue is recrystallized from ethyl alcohol. The title compound with a melting point of 13 0.5°C is obtained. Similarly produced are also the following compounds: [Key:] Beispiel = Example; Schmelzpunkt = Melting Point Example 4.0 Production of N-[2-(4-chlorophenyl)ethyl]-N2-(4-hydroxybenzyl)anthranilamide 71 mg of N-[2-(4-chlorophenyl)ethyl]-N2-(4-methoxybenzyl)anthranilamide is dissolved under nitrogen atmosphere in 2 ml of absolute dimethylformamide and mixed with 76 mg of sodium thiomethylate. The reaction mixture is refluxed for 1.5 hours. After cooling, it is mixed with 30 ml of water and then extracted with ethyl acetate. The organic phase is washed, dried, filtered and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel with hexane + ethyl acetate (7+3) as an eluant. 23 mg of the title compound with a melting point of 103-105°C is obtained. Example 5.0 Production of 2-[ (-2-chloropyridin-4-yl)methyl]amino]-N-(isoquinolin-3-yl)benzoic acid amide 300 mg of 2-[amino]-N-(isoquinolin-3-yl)benzoic acid amide is mixed in 6 ml of methanol with 0.06 ml of glacial acetic acid and 523 mg of a 39% solution of 2-chloro-4-pyridine carbaldehyde in methylene chloride and ethyl acetate, and it is stirred for 20 hours at room temperature under argon. Then, 96 mg of sodium cyanoborohydride is added, and it is stirred for 6. hours at room temperature. After concentration by evaporation in a vacuum, the residue is taken up in 3 0 ml of a dilute solution of sodium bicarbonate in water and extracted with ethyl acetate. The ethyl acetate phase is washed with water, dried, filtered and concentrated by evaporation. The residue is chromatographed on silica gel with ethyl acetate as an eluant. After the corresponding fractions are combined and concentrated by evaporation, 56 mg of 2-[(-2-chloropyridin-4-yl)methyl]amino]-N-(isoquinolin-3-yl)benzoic acid amide is obtained. Similarly produced are also the following compounds [Key:] Beispiel = Example; Schmelzpunkt = Melting Point [Key. ] Beispiel = Example; Schmelzpunkt = Melting Point Example 6.0 Production of 2-[[(1,2-dihydro-l-methyl-2-oxopyridin-4-yl)methyl]amino]-N-(isoquinolin-3-yl)benzoic acid amide 8 0 mg of 2-[[(1,2-dihydro-2-oxopyridin-4-yl)methyl]amino]-N-(isoquinolin-3-yl)benzoic acid amide in 2 ml of dimethylformamide is mixed under argon with 10 mg of sodium hydride (80%) and heated for 3 0 minutes to 6 0°C. Then, 0.015 ml of methyl iodide in 0.5 ml of dimethylformamide is added in drops and heated for 1 hour to 60°C. After cooling, the batch is added to a solution of sodium bicarbonate and extracted with ethyl acetate. The ethyl acetate phase is washed, dried and concentrated by evaporation, and the residue on silica gel with methylene chloride:ethanol = 97:3 as an eluant. 3 0 mg of 2-[[(l,2-dihydro-1-methyl-2-oxopyridin-4-yl)methyl]amino] -N-(isoquinolin-3-yl)benzoic acid amide is obtained. Similarly produced are also the following compounds: [Key:] Beispiel = Example; Schmelzpunkt = Melting Point Example 7.0 Production of 2-[(-2-methoxypyridin-4-yl)methyl]amino]-N-(isoquinolin-3-yl)benzoic acid amide and 2-[[(1,2-dihydro-l-methyl-2-oxopyridin-4-yl)methyl]amino]-N-(isoquinolin-3-yl)benzoic acid amide 13 0 mg of 2-'[[(1,2-dihydro-2-oxopyridin-4-yl)methyl]amino]-N-(isoquinolin-3-yl)benzoic acid amide is introduced into 4 ml of a mixture that consists of toluene:methanol = 1:3.5 and mixed with 0.2 ml of a 2-molar solution of trimethylsilyldiazomethane in hexane and stirred for 8 hours at room temperature. After repeated addition of 0.2 ml of trimethylsilyldiazomethane solution and 1 hour of stirring, the batch is evaporated to the dry state and chromatographed on silica gel with methylene chloride:ethanol = 97:3 as an eluant. 2 0 mg of 2-[(-2-methoxypyridin-4-yl)methyl]amino]-N-(isoquinolin-3-yl)benzoic acid amide and 10 mg of 2-[[(1,2-dihydro-l-methyl-2-oxopyridin-4-yl)methyl]amino]-N-(isoquinolin-3-yl)-benzoic acid amide are obtained. Similarly produced are also the following compounds: [Key:] Beispiel = Example; Schmelzpunkt = Melting Point Example 8.0 Production of N-(indazol-5-yl) N2-(4-pyridylmethyl)-anthranilic acid amide 228 mg of N-(4-pyridylmethyl)-anthranilic acid is introduced into 10 ml of dimethylformamide under argon and in a moisture-free environment. 2 66 mg of 5-aminoindazole, 0.2 7 ml of methylmorpholine and 456 mg of 0-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) are added. The mixture is then stirred for 4 hours at room temperature. It is then mixed with dilute sodium bicarbonate solution and extracted three times with ethyl acetate. The combined organic phases are washed with water, dried, filtered and concentrated by evaporation in a vacuum. The residue is chromatographed on silica gel with ethyl acetate as an eluant. By absorptive precipitation in acetone, 245 mg of the title compound with a melting point of 2 09.8°C is obtained. Similarly produced are also the following compounds: [Key.] Beispiel = Example; Schmelzpunkt = Melting Point [Key:] Beispiel = Example; Schmelzpunkt = Melting Point [Key:] Beispiel = Example; Schmelzpunkt = Melting Point The following example explains the production of the intermediate products according to the invention, without limiting the invention to these examples. Example 9.0 Production of N-(4-methoxybenzyl)isatoic acid anhydride as an intermediate product for the production of the end products according to the invention. Under nitrogen atmosphere, a solution that consists of 5 g of isatoic acid anhydride and 100 ml of N,N-dimethylacetamide is cooled in an ice bath and mixed in portions with 1.35 g of sodium hydride (oil - 60%). The reaction mixture is then stirred for 30 minutes at room temperature and for another 3 0 minutes at a bath temperature of 60°C. After cooling to room temperature, 5 ml of 4-methoxybenzaldehyde is added in drops while being stirred, and it is stirred overnight at room temperature. The reaction mixture is concentrated by evaporation in a vacuum and poured onto 100 ml of ice/water. The precipitate is separated, taken up in 50 ml of methylene chloride, washed, dried, filtered and concentrated by evaporation in a vacuum. The residue is recrystallized from alcohol. 3.4 g of the title compound with a melting point of 143°C is obtained. Similarly produced are also the following compounds: [Key:] Beispiel = Example; Schmelzpunkt = Melting Point Example 10.0 Production of N-(4-pyridylmethyl)-anthranilic acid as an intermediate product for the production of the end products according to the invention 2 g of N-(4-pyridylmethyl)-anthranilic acid methyl ester is dissolved in 15 ml of methanol, mixed with 16 ml of IN sodium hydroxide solution and refluxed for 1 hour. After cooling, the methanol is distilled off under vacuum, and the residue is mixed with 20 ml of water and 20 ml of IN citric acid solution. The crystals are suctioned off, washed with water and dried. 1.7 g of the title compound with a melting point of 208.0°C is obtained. Example 11.0 Production of N-(indazol-5-yl)-5-chloroanthranilic acid amide as an intermediate product for the production of the end products according to the invention 171 mg of 5-chloroanthranilic acid is introduced into 10 ml of dimethylformamide under argon and in a moisture-free environment and mixed in succession with 2 53 mg of N-methylmorpholine, 266 mg of 5-aminoindazole and 456 mg of 0-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) and stirred for 4 hours at room temperature. After standing overnight, it is mixed with 50 ml of water and extracted with 3 0 ml of ethyl acetate. The organic phase is washed with water, dried, filtered and concentrated by evaporation. The residue is chromatographed on silica gel with ethyl acetate as an eluant. 266 mg of N-(indazol-5-yl)-5-chloroanthranilic acid amide is obtained. The following sample applications explain the biological action and use of the compounds according to the invention without limiting the latter to the examples. Solutions required for the tests Stock solutions Stock solution A: 3 mmol of ATP in water, pH 7.0 (-70°C) Stock solution B: g-33P-ATP 1 mCi/100 μl Stock solution C: poly-(Glu4Tyr) 10 mg/ml in water Solution for dilutions Substrate solvent: 10 mmol of DTT, 10 mmol of manganese chloride, 10 0 mmol of magnesium chloride Enzyme solution: 120 mmol of tris/HCl, pH 7.5, 10 μm of sodium vanadium oxide Sample Application 1 Inhibition of the KDR- and FLT-1 kinase activity in the presence of the compounds according to the invention In a microtiter plate (without protein binding) that tapers to a point, 10 μl of substrate mixture (10 μl of vol of ATP stock solution A + 25 /μCi of g-33P-ATP (about 2.5 μl of stock solution B) + 30 μl of poly-(Glu4Tyr) stock solution C + 1.21 ml of substrate solvent) , 10 μl of inhibitor solution (substances that correspond to the dilutions, as a control 3% DMSO in substrate solvent), and 10 μl of enzyme solution (11.25 μg of enzyme stock solution (KDR or FLT-1 kinase) is diluted at 4°C in 1.25 ml of enzyme solution) are added. It is thoroughly mixed and incubated for 10 minutes at room temperature. Then, 10 μl of stop solution (250 mmol of EDTA, pH 7.0) is added, mixed, and 10 μl of the solution is transferred to a P 81 phosphocellulose filter. Then, it is washed several times in 0.1 M phosphoric acid. The filter paper is dried, coated with Meltilex and measured in a microbeta counter. The IC50 values are determined from the inhibitor concentration, which is necessary to inhibit the phosphate incorporation to 50% of the uninhibited incorporation after removal of the blank reading (EDTA-stopped reaction). The results of kinase-inhibition IC50 in /nnol are depicted in the following table: Beispiel-Nr. VEGFR I (FLT) VEGFR II (KDR) 2.0 0,05 0,05 2.1 0,01 0,3 2.2 0,1 0,5 2.3 0,02 0,02 2.4 0,02 0.1 2.5 1 10 2.6 0,2 2 2.8 0,5 0,1 2.9 5 1 2.10 3 10 2.11 0,02 0,2 2.12 0,7 3 2.13 0,7 3 2.14 0,5 0,3 2.15 1,0 . KH 2.16 0,1 0.2 2.17 0,4 0.5 2.18 0,3 0.5 2.19 >10 >10 [Key:] Beispiel-Nr. = Example No. Beispiel-Nr. VEGFR I (FLT) VEGFR II (KDR) 2.20 4 KH 2.21 2 0,3 2.23 0,02 0,67 2.24 0,5 >1 2.25 0.3 0,2 2.26 0,2 0,2 2.27 0,02 0,02 2.28 1 2 2.29 2 3 2.30 0,005 0,02 2.31 0,1 0,27 2.32 0,02 0,02 2.33 1 2 2.34 2 0,1 2.35 0,098 0,02 2.36 0,05 0,2 2.37 0,2 2.38 7 0,2 2.39 0,05 0,03 2.40 0,5 2.41 1 0,3 2.42 0,5 0,1 2.43 0,02 0,05 2.44 . 0.3 0.2 2.45 0,1 1 2.46 0.04 0,05 2.47 0,02 1 2.48 0,1 0,5 [Key -. 1 Beispiel-Nr. = Example No. Beispiel-Nr. VEGFR I (FUT) VEGFR II (KDR) 2.49 0,08 0,05 2.50 KH KH 2.51 2.52 0,05 2.53 0,02 0,02 2.54 .0,02 0,005 2.55 0,3 0.2 2.56 0,04 0,02 2.57 KH KH 2.58 0,5 5 2.59 50 KH 2.60 0,5 0,7 2.61 10 10 2.63 0,0003 2.64 0,04 0,04 2.65 0,0002 2.74 1 KH 2.75. 0.3 5 3.0 KH 3,0 3.2 2,0 2,0 4.0 0,5 0,2 8.0 0,04 0.04 8.2 0,2 0,2 8.3 0,05 0,04 8.8 0,05 0,02 8.9 • 0,5 0,5 8.10 0*02 0,02 8.11 0,2 1 [Key:] Beispiel-Nr. = Example No. Beispiel-Nr. VEGFR I (FLT) VEGFR II (KDR) 8.12 0,2 0,1 8.13 0,5 0.5 8.14 0,5 0,2 8.15 0,2 0,2 8.16 0,2 0.3 8.17 0.05 8.18 0,05 KH= keine Hemmung [Key:] Beispiel-Nr. = Example No.' KH = keine Hemmung = No inhibition We claim: 1. A process for the production of the anthranilic acid amide compounds of formula I in which A W stands for the group =NR2, stands for oxygen, sulfur, two hydrogen atoms or the group =NR8, stands for the group =NR10 or =N-, -N(R10) - (CH2) - , branched or unbranched C,.6 allcyl or the group or A, Z and R1 together form the group m, n and o stand for 0-3, q stands for 1-6, Ra, Rb, Rc, Rd, R , Rf, independently of one another, stand for hydrogen, C1-4 alkyl or the group =NR10, and/or Ra and/or Rb can form a bond with Rc and/or Rd or Rc can form a bond with Re and/or Rf, or up to two of radicals Ra-Rf can close a bridge with up to 3 C-atoms each to form R1 or R2, X stands for the group =NR9 or =N-, Y stands for the group -(CH2) , P stands for 1-4, R1 stands for C1-6 alkyl that is unsubstituted or is optionally substituted in one or more places with R2 halogen, C1-6 alkyl, in one or more places with halogen, or aryl or heteroaryl that is substituted with C1-6 alkoxy, with the exception of Compounds in which aryl is bonded right in the =NR2 group in the meaning of A, Stands for hydrogen or C1-6 alkyl or Sorms a bridge with up to 3 ring members With Ra-Rf from Z or to form R,, R3 Stands for monocyclic or bicyclic aryl Or heteroaryl that is unsubstituted or Optionally substituted in one or more Places with halogen, C1-6 alkyl, C1-6 alkoxy or hydroxy, R4, R5, R6, and R7, independently of one another, stand for hydrogen, halogen, or C1-6 alkoxy, C1-6 alkyl or C1-6 carboxylalkyl that is Unsubstituted or optionally substituted in one or more places with halogen, or Rs and R6 together form the group R8, R9, and R10, independently of one another, stand for hydrogen or C1-6 alkyl, as well as their isomers and salts, stop a tyrosine phosphorylation or persistent angiogenesis and thus prevent the growth and propagation of tumors. If R2 fotms a bridge to R1, heterocycles are produced to which R1 is fused. For example, there can be mentioned: Ar If Ra, Rb, Rc, Rd, Rt, Rf, independently of one another, represent hydrogen or C1-4 alkyl, Z forms an alkyl chain. If Ra and/or Rb form a bond with Rc and/or Ra or Rc and/or Ra form a bond with Re and/or Rf, Z stands for an alkenyl or alkinyl chain. If Ra-Rf form a bridge on their own, Z represents a cycloalkyl or cycloalkenyl group. If up to two of radicals Ra-Rf form a bridge with up to 3 C atoms to R1, Z together with R1 is a benzo-or hetaryl-condensed (Ar) cycloalkyl are obtained in that a compound of formula II II in which R4 to R7 have the above meaning and T is H or a protective group and A is halogen or OR13, whereby R'3 means a hydrogen atom, C1-4 alkyl or C1-4, acyl, or a ring connects with T, wherein said process comprising alkylating N; converting COA into an amide and optionally cleaving protective groups or first converting into the amide and then N-alkylating to obtain the compound of formula I, Dated this 19th day of April, 2001 (RITUSHKA NEGI) Of Remfry & Sagar Attorney for the Applicants

Full Text

FORM 2
THE PATENTS ACT 1970
[39 OF 1970]
&
THE PATENTS RULES, 2003
COMPLETE SPECIFICATION
[See Section 10; rule 13]
"A PROCESS FOR THE PRODUCTION OF THE
ANTRHRANILIC ACID AMIDE COMPOUNDS"

SCHERING AKTIENGESELLSCHAFT, of Mullerstrasse 178, D-
13342 Berlin, Germany and NOVARTIS
AKTIENGESELLSCHAFT, of Schwarzwaldallee 215, CH-4058 Basel, Switzerland,
GRANTED
The following specification particularly describes the invention and the manner in which it is to be performed:

The invention relates to anthranilic acid amides and their use as pharmaceutical agents for treatment of diseases that are triggered by persistent angiogenesis as well as their intermediate products for the production of anthranilic acid amides.
Persistent angiogenesis can be the cause of various diseases such as psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy, fibrotic diseases, such as cirrhosis of the liver, mesangial-cell-proliferative diseases, and arteriosclerosis or can result in a progression of these diseases.
A direct or indirect inhibition of the VEGF receptor can be used for the treatment of such diseases and other VEGF-induced pathological angiogenesis and vascular permeable conditions, such as tumor vascularization. For example, it is known that by soluble receptors and antibodies against VEGF, the growth of tumors can be inhibited.
Persistent angiogenesis is induced by the VEGF factor via its receptor. So that VEFG can exert this action, it is

necessary that VEGF bonds to the receptor and a tyrosine phosphorylation is brought about.
Phenyl-anthranilamide derivatives are already known that are used as angiotensin II-antagonists (EP 564 356) and as antiinflammatory agents and anti-ulcera compounds (U.S. 3,409,668).
It has now been found that compounds of general formula I

in which A W

stands for the group =NR2,
stands for oxygen, sulfur, two hydrogen
atoms or the group =NR8,
stands for the group =NR10 or =N-,
-N(R10) - (CH2) -, branched or unbranched
C1-6 alkyl or the group

or A, Z and R1 together form the group

m, n and o stand for 0-3,
q stands for 1-6,
R , Rb, Rc, Rd, R , Rf, independently of one another, stand
for hydrogen, C1.4 alkyl or the group =NR10, and/or R and/or Rb can form a bond with Rc and/or Rd or Rc can form a
bond with Re and/or Rf, or up to two of
radicals Ra-Rf can close a bridge with
up to 3 C-atoms each to form R1 or R2,
X stands for the group =NR9 or =N-,
Y stands for the group -(CH2)p/
p stands for 1-4,
R1 stands for C1_6 alkyl that is
unsubstituted or is optionally substituted in one or more places with

halogen, C1-6 alkyl, in one or more places with halogen, or aryl or heteroaryl that is substituted with C1-6 alkoxy, with the exception of compounds in which aryl is bonded right in the =NR2 group in the meaning of A,
R2 stands for hydrogen or C1-6 alkyl or
forms a bridge with up to 3 ring members with Ra-Rf from Z or to form Rv
R3 stands for monocyclic or bicyclic aryl
or heteroaryl that is unsubstituted or optionally substituted in one or more places with halogen, C1-6 alkyl, C1-6 alkoxy or hydroxy,
R4, R5, R6, and R7, independently of one another, stand for
hydrogen, halogen, or C1-6 alkoxy, C1-6 alkyl or C1-6 carboxylalkyl that is unsubstituted or optionally substituted in one or more places with halogen, or R5 and R6 together form the group
0
CH2 0
R8, R9, and R10, independently of one another, stand for
hydrogen or C1-6 alkyl,
as well as their isomers and salts, stop a tyrosine phosphorylation or persistent

angiogenesis and thus prevent the growth

and propagation of tumors. If R2 forms a bridge to R1, heterocycles are produced to which R1 is fused. For example, there can be mentioned:

If Ra, Rfa, Rc, Rd, Re, Rf/ independently of one another, represent hydrogen or C1-4 alkyl, Z forms an alkyl chain.

If Ra and/or Rb form a bond with Rc and/or Rd or Rc and/or Rd form a bond with Re and/or Rf, Z stands for an alkenyl or alkinyl chain.
If Ra-Rf form a bridge on their own, Z represents a cycloalkyl or cycloalkenyl group.
If up to two of radicals Rg-Rf form a bridge with up to 3 C atoms to R1, Z together with R1 is a benzo- or hetaryl-condensed (Ar) cycloalkyl.
For example, there can be mentioned:

If one of radicals Rg-Rf closes a bridge to form R2, a nitrogen heterocycle that can be separated from R1 by a group is formed.
For example, there can be mentioned:

Alkyl is defined in each case as a straight-chain or branched alkyl radical, such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, pentyl, isopentyl or hexyl, whereby C1-4 alkyl radicals are preferred.
Cycloalkyl is defined respectively as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

Cycloalkenyl is defined respectively as cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, whereby the linkage can take place both to the double bond and to the single bonds.
Halogen is defined respectively as fluorine, chlorine, bromine or iodine.
The alkenyl and alkinyl substituents are in each case straight-chain or branched and contain 2-6 C atoms, preferably 2-4 C atoms. For example, the following radicals can be mentioned: vinyl, propen-1-yl, propen-2-yl, but-1-en-l-yl, but-l-en-2-yl, but-2-en-i-yl, but-2-en-2-yl, 2-methyl-prop-2-en-l-yl,- 2-methyl-prop-1-en-l-yl, but-l-en-3-yl, ethinyl, prop-1-in-l-yl, but-l-in-1-yl, but-2-in-l-yl, but-3-en-l-yl, allyl.
In each case, the aryl radical has 6-12 carbon atoms, such as, for example, naphthyl, biphenyl and especially phenyl.
In each case, the heteroaryl radical can be benzocondensed. For example, there can be mentioned as 5-ring heteroaromatic compounds: thiophene, furan, oxazole, thiazole, imidazole, pyrazole and benzo derivatives thereof, and as 6-ring-heteroaromatic compounds pyridine, pyrimidine, triazine, quinoline, isoquinoline and benzo derivatives, whereby in the case of benzocondensed heteroaryl radicals, the binding can be both to the heterocycle and to the benzo ring.
In each case, the aryl radical and the heteroaryl radical can be substituted by the same or a different component in 1, 2 or 3 places with halogen, C1-4 alkoxy, nitro, trifluoromethyl, trifluoromethoxy, cyano, SOqR5 or C1-4 alkyl, whereby q stands for 0-2.

If an acid group is included, the physiologically compatible salts of organic and inorganic bases are suitable as salts, such as, for example, the readily soluble alkali and alkaline-earth salts as well as N-methyl-glucamine, dimethyl glucamine, ethyl glucamine, lysine, 1,6-hexadiamine, ethanolamine, glucosamine, sarcosine, serinol, tris-hydroxy-methyl-amino-methane, aminopropanediol, Sovak base, l-amino-2,3,4-butanetriol.
If a basic group is included, the physiologically compatible salts of organic and inorganic acids are suitable, such as hydrochloric acid, sulfuric acid, phosphoric acid, citric acid, tartaric acid, i.a.
Those compounds of general formula I in which
A stands for the group =NR2,
W stands for oxygen, sulfur, two hydrogen
atoms or the group =NR8,
Z stands for the group =NR10, =N- or
or A, Z and R1 together form the group
-N(R10) - (CH2)4- branched or unbranched C1-6 alkyl or the group

m, n, and o stand for 0-3,
q stands for 1-6,
R , R. , R , R.; R and R,, independently of one another, stand
for hydrogen, C1-4 alkyl or the group =NR10,
X stands for the group =NR9 or =N-,
Y stands for the group -(CHJ ,
p stands for 1-4,
R1 stands for phenyl, pyridyl, 5-chloro-
2,3-dihydroindenyl, 2,3-dihydroindenyl, thienyl, 6-fluoro-lH-indol-3-yl, naphthyl, 1,2,3,4 -1etrahydronaphthyl, benzo-1,2,5-oxadiazole, 6,7-dimethoxy-1,2,3,4-tetrahydro-2-naphthyl or for phenyl or pyridyl that is substituted in one or more places with C1-C4 alkyl, C1-

C4 alkoxy, hydroxy, halogen, or trifluoromethyl, or for the group

whereby phenyl, substituted phenyl or naphthyl is not right in the =NR2 group in the meaning of A,
R2 stands for hydrogen or C1-6 alkyl or
forms a bridge with up to 3 ring members with Ra-Rf from Z or to form R1,
R3 stands for monocyclic or bicyclic aryl
or monocyclic or bicyclic heteroaryl that is unsubstituted or optionally substituted in one or more places with halogen, C1-6alkyl, C1-6 alkoxy or hydroxy,
R4, R5, R6 and R7, independently of one another, stand for
hydrogen, halogen or C1-6 alkoxy or C1-6 alkyl that is unsubstituted or optionally substituted in one or more places with halogen, or R5 and R6 together form the group

R8, R9 and R10, independently of one another, stand for
hydrogen or C^ alkyl, as well as their isomers and salts, have proven especially effective.

preferred are compounds of general formula I

stands for the group =NR2,
stands for oxygen, sulfur or two
hydrogen atoms,
stands for the group =NR10, =N-, -N(R10)
(CH2) - or the group

or A, Z and R1 together form the group

m, n and o stand for 0-3,
q stands for 1-6,
Ra' Rb' Rc' Rd' Re' Rf independently of one another, stand
for hydrogen or methyl or the group
=NR10,
X stands for the group =NR9 or =N-,
Y stands for the group -CH2-,
R1 stands for phenyl, pyridyl, 5-chloro-
2,3-dihydroindenyl, 2,3-dihydroindenyl, thienyl, 6-fluoro-lH-indol-3-yl, naphthyl, 1,2,3,4-tetrahydronaphthy1, benzo-l,2,5-oxadiazole, 6,7-dimethoxy-l,2,3,4-tetrahydro-2-naphthyl, or for phenyl or pyridyl that is substituted in one or more places with C1-C4 alkyl, C1-C4 alkoxy, hydroxy, halogen, trifluoromethyl, or for the group

whereby phenyl, or substituted phenyl or
naphthyl is not right in the =NR2 group
in the meaning of A,
stands for hydrogen or methyl,
stands for pyridyl or phenyl, pyridyl or
1,2,3,4-tetrahydronaphthyl that is
substituted with hydroxy, halogen,
methyl or methoxy, or the group

R5 and R6, independently of one another, stand for
hydrogen, halogen, methyl, methoxy or
trifluoromethyl,
R4 and R7, independently of one another, stand for
hydrogen or halogen,
R9 stands for hydrogen,
R10 stands for hydrogen or methyl,
as well as their isomers and salts.
Those compounds of general formula I in which
A stands for the group =NR2, _
W stands for oxygen,
z stands for the group =NR10, =N-, -N(R10)-
or A, Z and R1 together form the group
(CH2) - or the group

m, n and o stand for 0-3,
q stands for 1-6,
Ra, Rb, Rc, Rd, Re, Rf, independently of one another, stand
for hydrogen or methyl or the group
=NR1°,
X stands for the group =NR9 or =N-,
Y stands for the group -CH2-,
R1 stands for phenyl, pyridyl, 5-chloro-
2,3-dihydroindenyl, 2,3-dihydroindenyl, thienyl, 6-fluoro-1H-indol-3-yl, naphthyl, 1,2,3,4-tetrahydronaphthyl, benzo-1,2,5-oxadiazole or 6,7-dimethoxy-1,2,3,4-tetrahydro-2-naphthyl or for a phenyl or pyridyl that is substituted in one more places with C1-C4 alkyl, C1-C4 alkoxy, hydroxy, halogen, trifluoromethyl, or for the group

whereby phenyl, or substituted phenyl or naphthyl is not right in the =NR2 group in the meaning of A, stands for hydrogen or methyl,

stands for pyridyl or for phenyl, pyridyl or 1,2,3,4 -tetrahydronaphthyl that is substituted in one or more places with hydroxy, halogen, methyl or methoxy, or for the group

R5 and R6, independently of one another, stand for
hydrogen, halogen, methyl, methoxy, or
trifluoromethyl,
R4 and R7, independently of one another, stand for
hydrogen and halogen,
R9 stands for hydrogen,
R10 stands for hydrogen or methyl,
as well as their isomers and salts, have proven quite especially effective.
Those compounds of general formula I in which

stands for the group =NR2,
stands for sulfur,
stands for the group =NR10, =N-, -N(R10)
(CH2)4 - or the group

or A, Z and R1 together form the group

n and o

stand for 0-3, stands for 1-6,

Ra' Rb' Rc' Rd' Re' Rf/ independently of one another, stand
for hydrogen or methyl or the group
=NR10,
X stands for the group =NR9 or ==N-,
Y stands for the group -CH2-,
R stands for phenyl, pyridyl, 5-chloro-
2,3-dihydroindenyl, 2,3-dihydroindenyl, thienyl, 6-fluoro-lH-indol-3-yl, naphthyl, 1,2,3,4-tetrahydronaphthyl, benzo-1,2,5-oxadiazole or 6,7-dimethoxy-1,2,3,4-tetrahydro-2-naphthyl or for phenyl or pyridyl that is substituted in one or more places with C1-C4 alkyl, C1-4 alkoxy, hydroxy, halogen, trifluoromethyl, or for the group

whereby phenyl, or substituted phenyl or
naphthyl is not right in the =NR2 group
in the meaning of A,
R2 stands for hydrogen or methyl,
R3 stands for pyridyl or for phenyl,
pyridyl or l,2,3,4-tetrahydronaphthyl that is substituted in one or more places with hydroxy, halogen, methyl or methoxy, or for the group

R5 and R6, independently of one another, stand for
hydrogen, halogen, methyl, methoxy or
trifluoromethyl,
R4 and R7, independently of one another, stand for
hydrogen and halogen,
R9 stands for hydrogen,
R10 stands for hydrogen or methyl,
as well as their isomers and salts, have also proven quite especially effective.
Those compounds of general formula I in which
A stands for the group =NR2,
W stands for two hydrogen atoms,
Z stands for the group =NR10, =N-, -N(R10)-
or A, Z, and R1 together form the group
(CH2) - or the group

m, n and o stand for 0-3,
q stands for 1-6,
Ra, Rb, Rc, Rd, Re, Rf, independently of one another, stand
for hydrogen or methyl or the group
=NR10,
X stands for the group =NR9 or =N- ,
Y stands for the group -CH2-,
R1 stands for phenyl, pyridyl, 5-chloro-
2,3-dihydroindenyl, 2,3-dihydroindenyl, thienyl, 6-fluoro-lH-indol-3-yl, naphthyl, 1,2,3,4-tetrahydronaphthyl, benzo-1,2,5-oxadiazole or 6,7-dimethoxy-1,2,3,4-tetrahydro-2-naphthyl or for a phenyl or pyridyl that is substituted in one or more places with C1-4 alkyl, C1-4 alkoxy, hydroxy, halogen, or trifluoromethyl, or for the group

whereby phenyl, or substituted phenyl or naphthyl is not right in the =NR2 group in the meaning of A, stands for hydrogen or methyl, stands for pyridyl or for phenyl, pyridyl or 1,2,3,4 -tetrahydronaphthyl that is substituted in one or more places with hydroxy, halogen, methyl or methoxy, or for the group

RA and R7, independently of one another, stand for
hydrogen, halogen, methyl, methoxy or trifluoromethyl,
R5 and R6,
R,10
independently of one another, stand for hydrogen and halogen, stands for hydrogen, stands for hydrogen or methyl,
as well as their isomers and salts, have also proven quite
especially effective.
The compounds according to the invention prevent a
phosphorylation, i.e., certain tyrosine kinases can be inhibited
selectively, whereby the persistent angiogenesis can be stopped.
Thus, for example, the growth and the propagation of tumors is
suppressed.
The compounds of general formula I according to the
invention also include the possible tautomeric forms and comprise

the E- or Z-isomers, or, if a chiral center is present, also the racemates and enantiomers.
The compounds of formula I and their physiologically compatible salts can be used based on their inhibitory activity relative to the phosphorylation of the VEGF receptor as a pharmaceutical agent. Based on their profile of action, the compounds according to the invention are suitable for the treatment of diseases that are caused by persistent angiogenesis.
Since the compounds of formula I are identified as inhibitors of the tyrosine kinases KDR and FLT, they are suitable in particular for treatment of those diseases that are caused by the persistent angiogenesis that is triggered by the VEGF receptor or an increase of vascular permeability.
The subject of this invention is also the use of compounds according to the invention as inhibitors of the tyrosine kinases KDR and FLT.
The subjects of this invention are thus also pharmaceutical agents for the treatment of tumors.
The compounds according to the invention can be used either alone or in a formulation as pharmaceutical agents for the treatment of psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy, fibrotic diseases, such as

cirrhosis of the liver, mesangial-cell-proliferative diseases, arteriosclerosis and injuries to the nerve tissue.
The compounds according to the invention can also be used in inhibiting the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents.
In the treatment of injuries to the nerve tissue, a quick scar formation at the injury sites can be prevented with the compounds according to the invention, i.e., scars are prevented from forming before the axons are reconnected to one another. Reconstruction of the nerve connections thus would be facilitated.
The ascites formation in patients also can be suppressed with the compounds according to the invention. The VEGF-induced edemas can also be suppressed.
Such pharmaceutical agents, their formulations and uses are also the subject of this invention.
The invention also relates to the use of the compounds of general formula I, for the production of a pharmaceutical agent for treatment of tumors, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy, fibrotic diseases, such as cirrhosis of the liver, mesangial-cell-proliferative diseases, arteriosclerosis, injuries to the nerve tissue, inhibition of the

reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents.
To use the compounds of formula I as pharmaceutical agents, the latter are brought into the form of a pharmaceutical preparation, which in addition to the active ingredient for enteral or parenteral administration contains suitable pharmaceutical, organic or inorganic inert support media, such as, for example, water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc. The pharmaceutical preparations can be present in solid form, for example as tablets, coated tablets, suppositories, capsules or in liquid form, for example as solutions, suspensions or emulsions. Moreover, they optionally contain adjuvants such as preservatives, stabilizers, wetting agents or emulsifiers, salts for changing osmotic pressure or buffers.
For parenteral use, in particular injection solutions or suspensions, especially aqueous solutions of the active compounds in polyhydroxyethoxylated castor oil, are suitable.
As vehicle systems, surface-active adjuvants, such as salts of bile acids or animal or plant phospholipids, but also mixtures thereof as well as liposomes or components thereof can also be used.
For oral use, especially tablets, coated tablets or capsules with talc and/or hydrocarbon vehicles or binders, such as, for example, lactose, corn or potato starch, are suitable. The

application can also be carried out in liquid form, such as, for example, as juice, to which optionally a sweetener is added.
The dosage of the active ingredients can vary depending on the method of administration, age and weight of the patient, type and severity of the disease that is to be treated, and similar factors. The daily dose is 0.5-1000 mg, preferably 50-200 mg, whereby the dose can be given as a single dose to be administered once or subdivided into 2 or more daily doses.
The above-described formulations and forms for dispensing are also the subject of this invention.
The production of the compounds according to the invention is carried out according to methods that are known in the art. For example, compounds of formula I are obtained in that
a) A compound of formula II

in which R4 to R7 have the above meaning and T is H or a protective group and A is halogen or OR13, whereby R13 means a hydrogen atom, C1-4 alkyl or C1-4 acyl, or a ring connects with T, first alkylates N and then converts COA into an amide and then

optionally protective groups are cleaved or first converted into the amide and then N-alkylated, or
b) A compound of formula III
in which R4 to R7 have the above meaning and T means H or a protective group, is in orthometallated form, and then is converted into an amide by being caught with an electrophile, then the protective group is cleaved, and the amino group is alkylated, or
c) A compound of formula IV
in which R4 to R7 have the above meaning, and T means H or a protective group and B means halogen or O-filtrate, O-tosylate or O-mesylate, is converted into an amide, then the protective group is cleaved off, and the amino group is alkylated.
The sequence of the steps can be reversed in all three cases.
The amide formation is carried out according to methods that are known in the literature.
For amide formation, a start can be made from a corresponding ester. The ester is reacted according to J. Org. Chem. 1995, 8414 with aluminum trimethyl and the corresponding amine in solvents, such as toluene, at temperatures of 0°C up to the boiling point of the solvent. This method can also be used in unprotected anthranilic acid esters. If the molecule contains two ester groups, both are converted into the same amide.
When nitriles are used instead of ester, amidines are obtained under analogous conditions.

For amide formation, however, all processes that are known from peptide chemistry are also available. For example, the corresponding acid can be reacted in aprotic polar solvents, such as, for example, dimethylformamide on an activated acid derivative, that can be obtained, for example, with hydroxybenzotriazole and a carbodiimide such as, for example, diisopropylcarbodiimide or else with preformed reagents, such as, for example, HATU (Chem. Comm. 1994, 201) or BTU, at temperatures of between 0°C and the boiling point of the solvent, preferably at 8 0°C with the amine at HATU preferably at room temperature. These methods can also be used in the unprotected anthranilic acids. For amide formation, the process can also be used on the mixed acid anhydride, imidazolide or azide. A prior protection of the amino group, for example as amide, is not necessary in all cases, but can affect the reaction advantageously. Isatoic acid anhydrides, in which the protection of the amino group and the activation of the acidic function are present at the same time, are a special starting material.
If the amine is already converted into the BOC-protected compound, the ortho-position can be metallated by reaction with organometallic compounds, such as, for example, n-butyllithium, and then caught with isocyanates or isothiocyanates to form the anthranilamides or anthranilthioamides. A bromine or iodine substituent in this ortho-position facilitates the ortho-metallation by halogen-metal exchange. As solvents, ethers such as diethyl ether or tetrahydrofuran or hydrocarbon such as hexane, but also mixtures thereof, are suitable. The addition of

variant in aqueous solution at weakly alkaline pH or by reaction

with an anhydride in glacial acetic acid.
The introduction of the halogens chlorine, bromine, iodine or the azido group via an amino group can also be carried out, for example, according to Sandmeyer, by the diazonium salts that are formed as intermediate products with nitrites being reacted with copper(I) chloride or copper(I) bromide in the presence of the corresponding acid such as hydrochloric acid or hydrobromic acid or with potassium iodide.
If an organic nitrite is used, the halogens can be introduced into a solvent, such as, for example, dimethylformamide, e.g., by addition of methylene iodide or tetrabromomethane. The removal of the amino group can be achieved either by reaction with an organic nitrite in tetrahydrofuran or by diazotization and reductive boiling down of the diazonium salt with, for example, phosphorous acid optionally with the addition of copper(I) oxide.
The introduction of fluorine can be carried out by, for example, Balz-Schiemann reaction of the diazonium tetrafluoroborate or according to J. Fluor. Chem. 76, 1996, 59-62 by diazotization in the presence of HFxpyridine and subsequent boiling-down optionally in the presence of a fluoride ion source, such as, e.g., tetrabutylammonium fluoride.
The introduction of the azido group can be carried out after diazotization by reaction with sodium azide at room temperature.
Ether cleavages are performed according to processes that are common in the literature. In this case, a selective cleavage

products ior the production oi the compounds oi general ior-mula I according to the invention.
Especially valuable are those intermediate products of general formula V in which
A and W stand for oxygen,
Z and R' together form a =C=0 group that is
bonded to X,
X stands for the group s=NR9 or =N-,
Y stands for the group 'CH2~,
R3 stands for pyridyl or phenyl or 1,2,3,4-
tetrahydronaphthyl that is substituted by hydroxy, bromine, methyl or methoxy,
R5 and R6 stand for hydrogen, cfclorine, methyl,
methoxy or trifluoroethyl,
R4 and R7 stand for hydrogen,
R9 stands for hydrogen,
as well as their isomers and salts.
The intermediate products are partially active on their own and can thus also be used for the production of a pharmaceutical agent for the treatment of tumors, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy, fibrotic diseases, such as cirrhosis of the liver, mesangial-cell-proliferative diseases, arteriosclerosis, injuries to the nerve tissue, inhibition of the

According to commonly used methods, such as, for example, crystallization, chromatography or salt formation, the isomer mixtures can be separated into enantiomers or E/Z-isomers.
The production of the salts is carried out in the usual way, by a solution of the compound of formula I being mixed with the equivalent amount or an excess of a base or acid, which optionally is in solution, and the precipitate being separated or the solution being worked up in the usual way.
If the production of the starting compounds is not described, the latter are known or can be produced analogously to known compounds or processes that are described here.
Also subjects of this invention are the isatoic acid derivatives of general formula V

V,
in which R3-R7, X, Y and W have the meanings that are described in general formula I and in which A stands for the group =NR2 or oxygen, and Z and R1 together form a =C=0 group that is bonded to X, as well as their isomers and salts, as valuable intermediate

reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents.

can be achieved also in several groups that are present in the molecule. In this case, the ether is treated with, for example, boron tribromide in solvents such as dichloromethane at temperatures of between -100°C up to the boiling point of the solvent, preferably at -78°C. It is also possible, however, to cleave the ether by sodium thiomethylate in solvents such as dimethylformamide. The temperature can lie between room temperature and the boiling point of the solvent, preferably at 150°C.
The N- or O-alkylation of amides such as the pyrid-2-one or 2-hydroxypyridine can be carried out according to methods that are known in the literature. An N-alkylation thus can be achieved with bases such as sodium hydride or potassium carbonate in solvents such as dimethylformamide and alkylation with alkyl halides such as methyl iodide. An O-alkylation with bases such as silver carbonate in solvents such as tetrahydrofuran or toluene or preferably mixtures thereof with alkyl halides, such as methyl iodide. An O-alkylation is also obtained during conversion with trialkyloxonium tetrafluoroborate in inert solvents such as methylene chloride. Mixtures of N- and O-alkyl derivatives are obtained in the reaction with diazomethane or trimethylsilyldiazomethane in solvents such as methanol or toluene, preferably in mixtures thereof at temperatures up to the boiling point of the solvent, but preferably at room temperature. The methods make possible a selective alkylation of the pyridone relative to the benzoic acid amide.

The examples below explain the production of the compounds according to the invention without limiting the scope of the claimed compounds to these examples.
Example 1.0
Production of N-(4-Pyridylmethyl)-anthranilic acid methyl ester
Under nitrogen atmosphere, a mixture of 7.5 g of anthranilic acid methyl ester and 8.6 g of pyridine-4-carbaldehyde in 300 ml of methanol is mixed with 3 ml of acetic acid and stirred for 12 hours at room temperature. Then, the reaction mixture is mixed with 5.7 g of sodium cyanoborohydride (85%) and stirred for another 3 hours at room temperature. After this time, 1.14 g of sodium cyanoborohydride (85%) is added again and stirred for another 12 hours at room temperature. The reaction mixture is concentrated by evaporation. The residue is taken up in ethyl acetate and washed with saturated sodium bicarbonate solution and saturated sodium chloride solution. The dried organic phase is concentrated by evaporation, and the residue is purified with use of column chromatography on silica gel with use of hexane/ethyl acetate (1+1) .
10.2 g of the title compound with a melting point of 85.6°C is obtained.

Example 2.0
Production of N-(3-phenylprop-l-yl)-N2-(4-pyridylmethyl)-anthranilic acid amide
242 mg of N-(4-pyridylmethyl)-anthranilic acid methyl ester is introduced into 3.5 ml of toluene, mixed with 2 02 mg of 3-phenylpropylamine and quickly mixed at 0°C with 0.75 ml of a 2 molar solution of trimethylaluminum in toluene. The reaction mixture is then heated for 1 hour at room temperature and then refluxed for 1 hour. After cooling, the reaction mixture is added to saturated sodium bicarbonate solution and extracted with ethyl acetate. The organic phase is washed, dried, filtered and concentrated by evaporation in a vacuum. The residue is then recrystallized from ethyl acetate.
265 mg of the title compound with a melting point of 117.4°C is obtained.
Produced similarly to Example 2.0 are also the following compounds:

[Key:] Beispiel = Example; Schmelzpunkt = Melting Point

[Key:]
Beispiel = Example; Schraelzpunkt = Melting Point

[Key:]
Beispiel = Example; Schmelzpunkt = Melting Point

[Key:]
Beispiel = Example; Schmelzpunkt = Melting Point

[Key:] Beispiel = Example; Schmelzpunkt = Melting Point

[Key:]
Beispiel = Example; Schmelzpunkt = Melting Point

15

[Key:]
Beispiel = Example; Schmelzpunkt = Melting Point

[Key:]
Beispiel = Example; Schmelzpunkt = Melting Point

[Key:] Beispiel

= Example; Schmelzpunkt = Melting Point

Example 3.0
Production of N-(4-chlorobenzyl)-N2-(4-methoxybenzyl)anthranilamide
425 mg of N-(4-methoxybenzyl)isatoic acid anhydride is dissolved in 20 ml of tetrahydrofuran p.A., mixed with 234 mg of 4-chlorobenzylamine and refluxed for 4 hours. The reaction solution is concentrated by evaporation in a vacuum, taken up in ethyl acetate, washed, dried, filtered and concentrated by evaporation in a vacuum. The residue is recrystallized from ethyl alcohol. The title compound with a melting point of 13 0.5°C is obtained.
Similarly produced are also the following compounds:

[Key:] Beispiel = Example; Schmelzpunkt = Melting Point
Example 4.0
Production of N-[2-(4-chlorophenyl)ethyl]-N2-(4-hydroxybenzyl)anthranilamide
71 mg of N-[2-(4-chlorophenyl)ethyl]-N2-(4-methoxybenzyl)anthranilamide is dissolved under nitrogen atmosphere in 2 ml of absolute dimethylformamide and mixed with 76 mg of sodium thiomethylate. The reaction mixture is refluxed for 1.5 hours. After cooling, it is mixed with 30 ml of water and then extracted with ethyl acetate. The organic phase is washed, dried, filtered and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel with hexane + ethyl acetate (7+3) as an eluant.
23 mg of the title compound with a melting point of 103-105°C is obtained.

Example 5.0
Production of 2-[ (-2-chloropyridin-4-yl)methyl]amino]-N-(isoquinolin-3-yl)benzoic acid amide
300 mg of 2-[amino]-N-(isoquinolin-3-yl)benzoic acid amide is mixed in 6 ml of methanol with 0.06 ml of glacial acetic acid and 523 mg of a 39% solution of 2-chloro-4-pyridine carbaldehyde in methylene chloride and ethyl acetate, and it is stirred for 20 hours at room temperature under argon. Then, 96 mg of sodium cyanoborohydride is added, and it is stirred for 6. hours at room temperature. After concentration by evaporation in a vacuum, the residue is taken up in 3 0 ml of a dilute solution of sodium bicarbonate in water and extracted with ethyl acetate. The ethyl acetate phase is washed with water, dried, filtered and concentrated by evaporation. The residue is chromatographed on silica gel with ethyl acetate as an eluant. After the corresponding fractions are combined and concentrated by evaporation, 56 mg of 2-[(-2-chloropyridin-4-yl)methyl]amino]-N-(isoquinolin-3-yl)benzoic acid amide is obtained.

Similarly produced are also the following compounds

[Key:]
Beispiel = Example; Schmelzpunkt = Melting Point

[Key. ] Beispiel = Example; Schmelzpunkt = Melting Point

Example 6.0
Production of 2-[[(1,2-dihydro-l-methyl-2-oxopyridin-4-yl)methyl]amino]-N-(isoquinolin-3-yl)benzoic acid amide
8 0 mg of 2-[[(1,2-dihydro-2-oxopyridin-4-yl)methyl]amino]-N-(isoquinolin-3-yl)benzoic acid amide in 2 ml of dimethylformamide is mixed under argon with 10 mg of sodium hydride (80%) and heated for 3 0 minutes to 6 0°C. Then, 0.015 ml of methyl iodide in 0.5 ml of dimethylformamide is added in drops and heated for 1 hour to 60°C. After cooling, the batch is added to a solution of sodium bicarbonate and extracted with ethyl acetate. The ethyl acetate phase is washed, dried and concentrated by evaporation, and the residue on silica gel with methylene chloride:ethanol = 97:3 as an eluant. 3 0 mg of 2-[[(l,2-dihydro-1-methyl-2-oxopyridin-4-yl)methyl]amino] -N-(isoquinolin-3-yl)benzoic acid amide is obtained.

Similarly produced are also the following compounds:

[Key:] Beispiel = Example; Schmelzpunkt = Melting Point

Example 7.0
Production of 2-[(-2-methoxypyridin-4-yl)methyl]amino]-N-(isoquinolin-3-yl)benzoic acid amide and 2-[[(1,2-dihydro-l-methyl-2-oxopyridin-4-yl)methyl]amino]-N-(isoquinolin-3-yl)benzoic acid amide
13 0 mg of 2-'[[(1,2-dihydro-2-oxopyridin-4-yl)methyl]amino]-N-(isoquinolin-3-yl)benzoic acid amide is introduced into 4 ml of a mixture that consists of toluene:methanol = 1:3.5 and mixed with 0.2 ml of a 2-molar solution of trimethylsilyldiazomethane in hexane and stirred for 8 hours at room temperature. After repeated addition of 0.2 ml of trimethylsilyldiazomethane solution and 1 hour of stirring, the batch is evaporated to the dry state and chromatographed on silica gel with methylene chloride:ethanol = 97:3 as an eluant. 2 0 mg of 2-[(-2-methoxypyridin-4-yl)methyl]amino]-N-(isoquinolin-3-yl)benzoic acid amide and 10 mg of 2-[[(1,2-dihydro-l-methyl-2-oxopyridin-4-yl)methyl]amino]-N-(isoquinolin-3-yl)-benzoic acid amide are obtained.

Similarly produced are also the following compounds:

[Key:] Beispiel = Example; Schmelzpunkt = Melting Point

Example 8.0
Production of N-(indazol-5-yl) N2-(4-pyridylmethyl)-anthranilic acid amide
228 mg of N-(4-pyridylmethyl)-anthranilic acid is introduced into 10 ml of dimethylformamide under argon and in a moisture-free environment. 2 66 mg of 5-aminoindazole, 0.2 7 ml of methylmorpholine and 456 mg of 0-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) are added. The mixture is then stirred for 4 hours at room temperature. It is then mixed with dilute sodium bicarbonate solution and extracted three times with ethyl acetate. The combined organic phases are washed with water, dried, filtered and concentrated by evaporation in a vacuum. The residue is chromatographed on silica gel with ethyl acetate as an eluant.
By absorptive precipitation in acetone, 245 mg of the title compound with a melting point of 2 09.8°C is obtained.

Similarly produced are also the following compounds:

[Key.]
Beispiel = Example; Schmelzpunkt = Melting Point

[Key:]
Beispiel = Example; Schmelzpunkt = Melting Point

[Key:] Beispiel = Example; Schmelzpunkt = Melting Point

The following example explains the production of the intermediate products according to the invention, without limiting the invention to these examples.
Example 9.0
Production of N-(4-methoxybenzyl)isatoic acid anhydride as an intermediate product for the production of the end products according to the invention.
Under nitrogen atmosphere, a solution that consists of 5 g of isatoic acid anhydride and 100 ml of N,N-dimethylacetamide is cooled in an ice bath and mixed in portions with 1.35 g of sodium hydride (oil - 60%). The reaction mixture is then stirred for 30 minutes at room temperature and for another 3 0 minutes at a bath temperature of 60°C. After cooling to room temperature, 5 ml of 4-methoxybenzaldehyde is added in drops while being stirred, and it is stirred overnight at room temperature. The reaction mixture is concentrated by evaporation in a vacuum and poured onto 100 ml of ice/water. The precipitate is separated, taken up in 50 ml of methylene chloride, washed, dried, filtered and concentrated by evaporation in a vacuum. The residue is recrystallized from alcohol.
3.4 g of the title compound with a melting point of 143°C is obtained.

Similarly produced are also the following compounds:

[Key:] Beispiel

= Example; Schmelzpunkt = Melting Point

Example 10.0
Production of N-(4-pyridylmethyl)-anthranilic acid as an intermediate product for the production of the end products according to the invention
2 g of N-(4-pyridylmethyl)-anthranilic acid methyl ester is dissolved in 15 ml of methanol, mixed with 16 ml of IN sodium hydroxide solution and refluxed for 1 hour. After cooling, the methanol is distilled off under vacuum, and the residue is mixed with 20 ml of water and 20 ml of IN citric acid solution. The crystals are suctioned off, washed with water and dried.
1.7 g of the title compound with a melting point of 208.0°C is obtained.

Example 11.0
Production of N-(indazol-5-yl)-5-chloroanthranilic acid amide as an intermediate product for the production of the end products according to the invention
171 mg of 5-chloroanthranilic acid is introduced into 10 ml of dimethylformamide under argon and in a moisture-free environment and mixed in succession with 2 53 mg of N-methylmorpholine, 266 mg of 5-aminoindazole and 456 mg of 0-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) and stirred for 4 hours at room temperature. After standing overnight, it is mixed with 50 ml of water and extracted with 3 0 ml of ethyl acetate. The organic phase is washed with water, dried, filtered and concentrated by evaporation. The residue is chromatographed on silica gel with ethyl acetate as an eluant. 266 mg of N-(indazol-5-yl)-5-chloroanthranilic acid amide is obtained.

The following sample applications explain the biological action and use of the compounds according to the invention without limiting the latter to the examples.
Solutions required for the tests
Stock solutions
Stock solution A: 3 mmol of ATP in water, pH 7.0 (-70°C)
Stock solution B: g-33P-ATP 1 mCi/100 μl
Stock solution C: poly-(Glu4Tyr) 10 mg/ml in water
Solution for dilutions
Substrate solvent: 10 mmol of DTT, 10 mmol of manganese
chloride, 10 0 mmol of magnesium chloride Enzyme solution: 120 mmol of tris/HCl, pH 7.5, 10 μm of sodium
vanadium oxide
Sample Application 1
Inhibition of the KDR- and FLT-1 kinase activity in the presence of the compounds according to the invention
In a microtiter plate (without protein binding) that tapers to a point, 10 μl of substrate mixture (10 μl of vol of ATP stock solution A + 25 /μCi of g-33P-ATP (about 2.5 μl of stock solution B) + 30 μl of poly-(Glu4Tyr) stock solution C + 1.21 ml of substrate solvent) , 10 μl of inhibitor solution (substances that correspond to the dilutions, as a control 3% DMSO in substrate solvent), and 10 μl of enzyme solution (11.25 μg of enzyme stock solution (KDR or FLT-1 kinase) is diluted at 4°C in 1.25 ml of

enzyme solution) are added. It is thoroughly mixed and incubated for 10 minutes at room temperature. Then, 10 μl of stop solution (250 mmol of EDTA, pH 7.0) is added, mixed, and 10 μl of the solution is transferred to a P 81 phosphocellulose filter. Then, it is washed several times in 0.1 M phosphoric acid. The filter paper is dried, coated with Meltilex and measured in a microbeta counter.
The IC50 values are determined from the inhibitor concentration, which is necessary to inhibit the phosphate incorporation to 50% of the uninhibited incorporation after removal of the blank reading (EDTA-stopped reaction).

The results of kinase-inhibition IC50 in /nnol are depicted in the following table:

Beispiel-Nr. VEGFR I (FLT) VEGFR II (KDR)
2.0 0,05 0,05
2.1 0,01 0,3
2.2 0,1 0,5
2.3 0,02 0,02
2.4 0,02 0.1
2.5 1 10
2.6 0,2 2
2.8 0,5 0,1
2.9 5 1
2.10 3 10
2.11 0,02 0,2
2.12 0,7 3
2.13 0,7 3
2.14 0,5 0,3
2.15 1,0 . KH
2.16 0,1 0.2
2.17 0,4 0.5
2.18 0,3 0.5
2.19 >10 >10
[Key:] Beispiel-Nr. = Example No.

Beispiel-Nr. VEGFR I (FLT) VEGFR II (KDR)
2.20 4 KH
2.21 2 0,3
2.23 0,02 0,67
2.24 0,5 >1
2.25 0.3 0,2
2.26 0,2 0,2
2.27 0,02 0,02
2.28 1 2
2.29 2 3
2.30 0,005 0,02
2.31 0,1 0,27
2.32 0,02 0,02
2.33 1 2
2.34 2 0,1
2.35 0,098 0,02
2.36 0,05 0,2
2.37 0,2
2.38 7 0,2
2.39 0,05 0,03
2.40 0,5
2.41 1 0,3
2.42 0,5 0,1
2.43 0,02 0,05
2.44 . 0.3 0.2
2.45 0,1 1
2.46 0.04 0,05
2.47 0,02 1
2.48 0,1 0,5
[Key -. 1
Beispiel-Nr. = Example No.

Beispiel-Nr. VEGFR I (FUT) VEGFR II (KDR)
2.49 0,08 0,05
2.50 KH KH
2.51
2.52 0,05
2.53 0,02 0,02
2.54 .0,02 0,005
2.55 0,3 0.2
2.56 0,04 0,02
2.57 KH KH
2.58 0,5 5
2.59 50 KH
2.60 0,5 0,7
2.61 10 10
2.63 0,0003
2.64 0,04 0,04
2.65 0,0002
2.74 1 KH
2.75. 0.3 5
3.0 KH 3,0
3.2 2,0 2,0
4.0 0,5 0,2
8.0 0,04 0.04
8.2 0,2 0,2
8.3 0,05 0,04
8.8 0,05 0,02
8.9 • 0,5 0,5
8.10 0*02 0,02
8.11 0,2 1
[Key:]
Beispiel-Nr. = Example No.

Beispiel-Nr. VEGFR I (FLT) VEGFR II (KDR)
8.12 0,2 0,1
8.13 0,5 0.5
8.14 0,5 0,2
8.15 0,2 0,2
8.16 0,2 0.3
8.17 0.05
8.18 0,05
KH= keine Hemmung
[Key:]
Beispiel-Nr. = Example No.' KH = keine Hemmung = No inhibition

We claim:
1. A process for the production of the anthranilic acid amide compounds of formula I

in which A W

stands for the group =NR2,
stands for oxygen, sulfur, two hydrogen
atoms or the group =NR8,
stands for the group =NR10 or =N-,
-N(R10) - (CH2) - , branched or unbranched
C,.6 allcyl or the group

or A, Z and R1 together form the group

m, n and o stand for 0-3,
q stands for 1-6,
Ra, Rb, Rc, Rd, R , Rf, independently of one another, stand
for hydrogen, C1-4 alkyl or the group =NR10, and/or Ra and/or Rb can form a bond with Rc and/or Rd or Rc can form a bond with Re and/or Rf, or up to two of radicals Ra-Rf can close a bridge with up to 3 C-atoms each to form R1 or R2,
X stands for the group =NR9 or =N-,
Y stands for the group -(CH2) ,
P stands for 1-4,
R1 stands for C1-6 alkyl that is
unsubstituted or is optionally substituted in one or more places with

R2
halogen, C1-6 alkyl, in one or more places with halogen, or aryl or heteroaryl that is substituted with C1-6 alkoxy, with the exception of Compounds in which aryl is bonded right in the =NR2 group in the meaning of A, Stands for hydrogen or C1-6 alkyl or Sorms a bridge with up to 3 ring members With Ra-Rf from Z or to form R,,
R3 Stands for monocyclic or bicyclic aryl
Or heteroaryl that is unsubstituted or Optionally substituted in one or more Places with halogen, C1-6 alkyl, C1-6 alkoxy or hydroxy,
R4, R5, R6, and R7, independently of one another, stand for
hydrogen, halogen, or C1-6 alkoxy, C1-6 alkyl or C1-6 carboxylalkyl that is Unsubstituted or optionally substituted in one or more places with halogen, or Rs and R6 together form the group

R8, R9, and R10, independently of one another, stand for
hydrogen or C1-6 alkyl,
as well as their isomers and salts, stop a tyrosine phosphorylation or persistent

angiogenesis and thus prevent the growth and propagation of tumors. If R2 fotms a bridge to R1, heterocycles are produced to which R1 is fused. For example, there can be mentioned:

Ar

If Ra, Rb, Rc, Rd, Rt, Rf, independently of one another, represent hydrogen or C1-4 alkyl, Z forms an alkyl chain.

If Ra and/or Rb form a bond with Rc and/or Ra or Rc and/or Ra form a
bond with Re and/or Rf, Z stands for an alkenyl or alkinyl chain.
If Ra-Rf form a bridge on their own, Z represents a cycloalkyl or
cycloalkenyl group.
If up to two of radicals Ra-Rf form a bridge with up to 3 C atoms to R1, Z
together with R1 is a benzo-or hetaryl-condensed (Ar) cycloalkyl are
obtained in that a compound of formula II

II
in which R4 to R7 have the above meaning and T is H or a protective group and A is halogen or OR13, whereby R'3 means a hydrogen atom, C1-4 alkyl or C1-4, acyl, or a ring connects with T, wherein said process comprising alkylating N;
converting COA into an amide and
optionally cleaving protective groups or first converting into the amide
and then N-alkylating to obtain the compound of formula I,

Dated this 19th day of April, 2001
(RITUSHKA NEGI)
Of Remfry & Sagar
Attorney for the Applicants

Documents:

in-pct-2001-00422-mum-cancelled page(28-6-2005).pdf

in-pct-2001-00422-mum-claim(granted)-(28-6-2005).doc

in-pct-2001-00422-mum-claim(granted)-(28-6-2005).pdf

in-pct-2001-00422-mum-correspondence(ipo)-(28-6-2004).pdf

in-pct-2001-00422-mum-correspondence1(3-7-2004).pdf

in-pct-2001-00422-mum-correspondence2(28-6-2005).pdf

in-pct-2001-00422-mum-form 1(19-4-2001).pdf

in-pct-2001-00422-mum-form 19(27-4-2004).pdf

in-pct-2001-00422-mum-form 1a(28-6-2005).pdf

in-pct-2001-00422-mum-form 2(granted)-(28-6-2005).doc

in-pct-2001-00422-mum-form 2(granted)-(28-6-2005).pdf

in-pct-2001-00422-mum-form 3(19-4-2001).pdf

in-pct-2001-00422-mum-form 5(19-4-2001).pdf

in-pct-2001-00422-mum-power of authority(19-4-2001).pdf

in-pct-2001-00422-mum-power of authority(27-6-2005).pdf

« Previous Patent

Next Patent »

Patent Number

207347

Indian Patent Application Number

IN/PCT/2001/00422/MUM

PG Journal Number

30/2007

Publication Date

27-Jul-2007

Grant Date

06-Jun-2007

Date of Filing

19-Apr-2001

Name of Patentee

SCHERING AKTIENGESELLSCHAFT

Applicant Address

MULLERSTRASSE 178, D-13342 BERLIN,.

Inventors:

#	Inventor's Name	Inventor's Address
1	ANDREAS HUTH	DAMMWEG 113, D-12437, BERLIN.
2	ECKHARD OTTOW	MOLTKESTRASSE 48, D-12203 BERLIN, GERMANY.
3	MARTIN KRUGER	HEERUFER WEG 7A, D-13465 BERLIN, GERMANY.
4	ANDREAS MENRAD	ALLERSTRASSE 7, D-16515 ORANIENBURG, GERMANY.
5	MICHARL SCHIRNER	BIRKENALLEE 12, D-13158 BERLIN, GERMANY.
6	DIETER SEIDELMANN	STIERSTRASSE 14, D-12159 BERLIN, GERMANY.
7	KARL-HEINZ THIERAUCH	HOCHWILDPFAD 47, D-14169, BERLIN, GERMANY.
8	GUIDO BOLD	BLEUMATTHOHE 16, CH-5073 GIPF-OBERFRICK, SWITZERLAND.
9	PAUL WILLIAM MANLEY	BRUGGWEG 12, CH-4144 ARLESHEIM, SWITZERLAND.
10	PASCAL FURET	24, RUE DU RIEGELSBOURG, F-68800, THANN, FRANCE.
11	JEANETTE MARJORIE WOOD	IN DEN KLEEMATTEN 18, CH-4105 BIEL-BENKEN, SWITZERLAND.
12	JURGEN MESTEN	SIMON-VEIT-GASSE 4, D-79312 BIEL-BENKEN, EMMENDINGEN, GERMANY.
13	JOSE BRUGGEN	SCHUTZENGASSE 5, CH-4125 RIEHEN, SWITZERLAND.
14	STEFANO FERRARI	BASELSTRASSE 63, CH-4132 MUTTENZ, SWITZERLAND.

PCT International Classification Number

C07D 213/28

PCT International Application Number

PCT/EP99/08478

PCT International Filing date

1999-11-09

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1	199 10 396.8	1999-03-03	Germany
2	9824579.8	1998-11-10	Germany